These findings indicate that any antitumor therapy targeting glycolysis in the tumor microenvironment is a double-edged sword requiring enhancement of the glycolytic pathway to favor effector CD8 T cells while excluding side effects that promote the aggressive progression of tumor cells. The gene discussed is CD8A; the disease is neoplasm.